NEW YORK, March 22, 2016 /PRNewswire/ -- Immune Pharmaceuticals Inc. (NASDAQ: IMNP), ("Immune"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of immuno-inflammatory diseases and cancer, announced today the publication of a new study, which supports Immune's bispecific antibody platform. Preclinical results were published in The Journal of Immunology1 (http://www.ncbi.nlm.nih.gov/pubmed/26921308), by Dr. Jean Kadouche, scientific co-founder of Immune, and other collaborators from a consortium of academic centers. The authors describe the design and validation of a novel platform for the production of tetravalent IgG1-like bispecific antibodies, including final in-vivo proof-of-concept data for the benchmark molecule targeting HLA-DR/CD5. This work has been funded in part by a European grant to the collaborative European consortium (BMC) led by Dr. Kadouche.
Following the acquisition of licensing rights to this technology platform, Immune has initiated several bispecific antibody discovery programs. The first program targets two immune-checkpoints, PD-1 and Ox40. The second program targets one immune checkpoint, PD-L1, and one tumor-associated antigen, BCMA, a specific marker of multiple myeloma. The third program targets undisclosed antigens.
Dr. Boris Shor, Ph.D., Executive Director R&D, Immune stated: "We believe that this therapeutic platform provides Immune with a basis for developing innovative modalities targeting immune checkpoint proteins in a variety of cancer indications. Our future goal is to develop novel classes of antibody-based therapeutics for clinically-validated and novel targets. In 2016, we expect to complete initial validation of several bispecific antibody candidates for further development based on new data generated by our R&D team and supported by new intellectual property filed by Immune.
1 J Immunol. 2016 Apr 1;196(7):3199-211. doi: 10.4049/jimmunol.1501592. Epub 2016 Feb 26.
About Immune Pharmaceuticals:
Immune Pharmaceuticals (NASDAQ: IMNP) applies a personalized approach to development of, and treatment with, novel, highly targeted therapeutics to improve the lives of patients with inflammatory diseases and cancer. Immune's oncology pipeline includes bispecific antibodies, nanotherapeutics, including NanomAbs, and several mid-to-late stage small molecules, including Ceplene®, Azixa® and Crolibulin®. Ceplene is approved in over 30 European countries and Israel. Immune's lead product candidate for the treatment of inflammatory disease, bertilimumab, is in phase II clinical development for moderate-to-severe ulcerative colitis as well as for bullous pemphigoid, an orphan autoimmune dermatological condition. Other indications being considered for development include atopic dermatitis, Crohn's disease, severe asthma and NASH (an inflammatory liver disease). Immune recently expanded its portfolio in immuno-dermatology with topical nano-formulated cyclosporine-A for the treatment of psoriasis and atopic dermatitis. Immune's non-core pipeline includes AmiKet™, a late clinical stage drug candidate for the treatment of neuropathic pain. For more information, visit Immune's website at www.immunepharmaceuticals.com, the content of which is not a part of this press release.
This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal" or the negative of those words or other comparable words to be uncertain and forward-looking. Such forward-looking statements include statements that express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include, but not limited to: the risks associated with the adequacy of our existing cash resources and our ability to continue as a going concern; the risks associated with our ability to continue to meet our obligations under our existing debt agreements; the risk that clinical trials for bertilimumab or AmiKet will not be successful; the risk that bertilimumab, AmiKet or compounds arising from our NanomAbs program will not receive regulatory approval or achieve significant commercial success; the risk that we will not be able to find a partner to help conduct the Phase III trials for AmiKet on attractive terms, on a timely basis or at all; the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later-stage clinical trials; the risk that we will not obtain approval to market any of our product candidates; the risks associated with dependence upon key personnel; the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; the highly competitive nature of our business; risks associated with litigation; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings, which are available at www.sec.gov or at www.immunepharmaceuticals.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors. We expressly disclaim any obligation to publicly update any forward looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immune-pharmaceuticals-announces-publication-of-preclinical-data-in-support-of-its-bispecific-antibody-platform-in-the-journal-of-immunology-300239388.html
SOURCE Immune Pharmaceuticals Inc.